STOCK TITAN

[6-K] Nanobiotix S.A. American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
-
-
-
-
-
Positive
  • None.
Negative
  • None.
-
-
-
-
-
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 


On July 7, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated July 7, 2025


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Nanobiotix S.A.    
  (Registrant)
   
  
Date: July 7, 2025     /s/ Bart Van Rhijn    
  Bart Van Rhijn
  Chief Financial Officer
  

Nanobiotix S.A.

NASDAQ:NBTX

NBTX Rankings

NBTX Latest News

NBTX Latest SEC Filings

NBTX Stock Data

227.07M
47.32M
12.79%
0.06%
Biotechnology
Healthcare
Link
France
Paris